The effect of topical Imiquimod5% in treatment of high-grade cervical neoplasias (CIN2,3)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230811059116N1

Enrollment

Registered

2023-09-23

Start date

2023-10-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The recovery rate of high-grade cervical neoplasias.

Interventions

Intervention 1: Intervention group: the group receiving topical imiquimod 5%, for patients in the hospital, once a week with suitable study conditions and equipment, imiquimod cream 5% (250 mg) (Quimo

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age 20-45 years old Diagnosis of high-grade cervical neoplasia (CIN2,3) Obtaining informed consent

Exclusion criteria

Exclusion criteria: Cortone therapy Pregnancy Suppressed immune system due to HIV or organ transplant Prior treatment for HSIL

Design outcomes

Primary

Measure	Time frame
Cervical intraepithelial neoplasia (CIN). Timepoint: 12 weeks after using topical imiquimod cream5%. Method of measurement: Loop Electrosurgical Excision Procedure and histological examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNooshin Sarikhani

Iran University of Medical Sciences

nooshin_wxw@yahoo.com+98 21 8670 2503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026